Viewing StudyNCT02283177

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 3:25 AM
Last Modification Date: 2024-10-26 @ 11:33 AM
Study NCT ID: NCT02283177
Status: COMPLETED
Last Update Posted: 2024-02-02
First Post: 2014-10-29
Brief Title: A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations
Sponsor: Arog Pharmaceuticals Inc
Organization: Arog Pharmaceuticals Inc
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Newly Diagnosed AML With FLT3 Activating Mutations
Keywords: